scholarly journals Quality of Life in Patients with Low-Risk Prostate Cancer. A Comparative Retrospective Study: Brachytherapy Versus Robot-Assisted Laparoscopic Prostatectomy Versus Active Surveillance

2014 ◽  
Vol 28 (1) ◽  
pp. 117-124 ◽  
Author(s):  
Cenk Acar ◽  
Cecile C. Schoffelmeer ◽  
Corin Tillier ◽  
Willem de Blok ◽  
Erik van Muilekom ◽  
...  
Healthcare ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 14 ◽  
Author(s):  
Sabrina L. Dickey ◽  
Ciara J. Grayson

Prostate cancer is very common among men in the United States. The current literature on active surveillance (AS) suggests that it is a promising treatment option for men with low-risk prostate cancer. The purpose of this manuscript is to provide a thorough integrative review regarding the effects of AS on the quality of life (QoL) of men with prostate cancer. Utilizing a methodological strategy, electronic databases were reviewed for empirical articles during the time frame of January 2006 to December 2016. A total of 37 articles met the inclusion criteria wherein 20 focused on the QoL among men only receiving AS and 16 reported QoL among men undergoing AS and other forms of treatment for prostate cancer. The review highlights the purpose, common instruments, race and ethnicity, and strengths and limitations of each article. The majority of articles indicated low levels of anxiety and depression and decreased incidences of bladder, bowel and sexual functioning among men undergoing AS in comparison to men who received other treatment modalities. The results indicated that additional research is needed to determine the QoL among men receiving AS on a longitudinal basis. The results support previous literature that indicated the positive impact of AS on low-risk prostate cancer.


Cancer ◽  
2015 ◽  
Vol 121 (14) ◽  
pp. 2465-2473 ◽  
Author(s):  
Claudio Jeldres ◽  
Jennifer Cullen ◽  
Lauren M. Hurwitz ◽  
Erika M. Wolff ◽  
Katherine E. Levie ◽  
...  

JAMA Oncology ◽  
2019 ◽  
Vol 5 (5) ◽  
pp. 664 ◽  
Author(s):  
Deborah W. Bruner ◽  
Stephanie L. Pugh ◽  
W. Robert Lee ◽  
William A. Hall ◽  
James J. Dignam ◽  
...  

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16592-e16592
Author(s):  
Almudena Cascales ◽  
Maria Colmenero ◽  
Alfredo Rodriguez ◽  
Pilar Samper ◽  
Jeanette Valero ◽  
...  

2016 ◽  
Vol 21 (3) ◽  
pp. 207-212 ◽  
Author(s):  
Carlos Enrique Vargas ◽  
William Fred Hartsell ◽  
Megan Dunn ◽  
Sameer Ramchandra Keole ◽  
Lucius Doh ◽  
...  

2020 ◽  
Author(s):  
Penelope Schofield ◽  
Karla Gough ◽  
Amelia Hyatt ◽  
Alan White ◽  
Mark Frydenberg ◽  
...  

Abstract Background Active surveillance (AS) is the disease management option of choice for low risk prostate cancer. Despite this, men with low risk prostate cancer (LRPC) find management decisions distressing and confusing. We developed Navigate, an online decision aid to help men and their partners make management decisions consistent with their values. The aims are to evaluate the impact of Navigate on: uptake of AS; decision-making preparedness; decisional conflict, regret and satisfaction; quality of illness communication; and prostate cancer-specific quality of life and anxiety. In addition, the healthcare cost impact, cost-effectiveness and patterns of use of Navigate will be assessed. This paper describes the study protocol. Methods 304 men and their partners are randomly assigned one-to-one to Navigate or to the control arm. Randomisation is electronically generated and stratified by site. Navigate is an online decision aid that presents up-to-date, unbiased information on LRPC tailored to Australian men and their partners including each management option and potential side-effects; and an interactive values clarification exercise. Participants in the control arm will be directed to the website of Australia’s peak national body for prostate cancer. Eligible patients will be men within three months of being diagnosed with LRPC, aged 18 years or older and who are yet to make a treatment decision and who are deemed eligible for AS by their treating clinician, and who have internet access and sufficient English to participate. The primary outcome is self-reported uptake of AS as the first-line management option. Secondary outcomes include self-reported preparedness for decision-making; decisional conflict, regret and satisfaction; quality of illness communication; and prostate cancer-specific quality of life. Uptake of AS one month after consent will be determined through patient self-report. Men and their partners will complete study outcome measures before randomisation, and one, three and six months after study consent. Discussion The Navigate online decision aid has the potential to increase the choice of AS in LRPC, avoiding or delaying unnecessary radical treatments and associated side effects. In addition, Navigate is likely to reduce patients’ and partners’ confusion and distress in management decision-making, and increase their quality of life.


Sign in / Sign up

Export Citation Format

Share Document